博九娱乐网

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients…More with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies.